OncoPharm NSCLC In A Nutshell
Apr 19, 2024
Dive into the intricacies of non-small cell lung cancer treatment! Discover the latest advancements in targeted therapies and immunotherapy. The discussion emphasizes the importance of personalized treatment plans tailored to individual patient histories and genetic profiles. Explore how these developments can significantly impact patient outcomes in this evolving field of oncology.
AI Snips
Chapters
Transcript
Episode notes
NSCLC Overview and Diagnosis
- Non-small cell lung cancer (NSCLC) comprises about 85% of lung cancers and includes adenocarcinoma, squamous cell, and large cell carcinoma.
- Most NSCLC patients present at stage 3 or 4 due to smoking-related symptoms being mistaken or screened inadequately.
Use Lung Cancer Screening
- Patients with 20-pack year smoking history, aged 55 to 80, should get low-dose CT scans for lung cancer screening.
- Despite this, screening uptake remains low, missing prevention opportunities.
Traditional NSCLC Treatments
- Historically, early-stage NSCLC was treated with surgery and adjuvant chemotherapy, while advanced stages got chemoradiation or platinum doublets.
- Treatment was limited, toxic, and rarely curative beyond early disease stages before recent advances.